drugset / Trial / NCT01726023

Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

NCT01726023

Phase 3 Completed 486 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.

Timeline

Start
2013-01
Primary completion
2015-03
Completion
2015-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftazidime Small molecule 2000 mg Intravenous
Comparator Meropenem Small molecule 1000 mg
Subject Metronidazole Small molecule 500 mg Intravenous
Subject avibactam Small molecule 500 mg Intravenous

Indications

No indication recorded.